Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push
This article was originally published in The Pink Sheet Daily
Executive Summary
Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.
You may also be interested in...
BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?
Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up
BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?
Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up
Follow-On Biologics Coding Tweaks Could Raise Savings By 30% – CBO
Giving a follow-on biologic the same reimbursement code as its brand name counterpart would increase the savings from FOBs by 30 percent for the federal government's mandatory health care programs, the Congressional Budget Office estimates